Evaluating a new ultrasound score for blood volume management in children
Evaluation of the Venous Excess Ultrasound Score (VExUS) After Circulating Volume Modification in Children. VExUS-Mod
This study is testing a new ultrasound score to see if it can help doctors manage blood volume in children during medical procedures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 56 (estimated) |
| Ages | 1 Year to 18 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06695546 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the Venous Excess Ultrasound Score (VExUS) in children undergoing procedures that modify circulating blood volume. The VExUS score is designed to assess the impact of venous overload on organ perfusion and prognosis in intensive care settings. While initially validated in adults, this study seeks to explore its applicability and feasibility in a pediatric population, particularly in relation to central venous pressure and renal function. The study involves ultrasound evaluations to gather data on blood volume changes in children aged 1 to 18 years.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 1 to 18 years who are receiving extrarenal purification or experiencing significant bleeding or vascular filling.
Not a fit: Patients who may not benefit include those with known abnormalities of the hepatorenal venous network or those unable to tolerate the ultrasound examination.
Why it matters
Potential benefit: If successful, this study could improve the management of blood volume in critically ill children, potentially enhancing their outcomes.
How similar studies have performed: While the VExUS score has been validated in adults, its application in children is still being explored, indicating a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Children aged between 1 and 18 years, receiving extrarenal purification with UF \> 10 ml/kg, bleeding \> 10 ml/kg or vascular filling \> 10 ml/kg Exclusion Criteria: * Refusal of the patient or opposition of one or both holders of parental authority. * Minors with parental authority. * Ultrafiltration time \> 6h. * Curarized patient, known abnormality of the hepatorenal venous network. * Patient agitated or poor tolerance of the examination. * Parents under court protection, guardianship or curatorship.
Where this trial is running
Toulouse
- CHU Toulouse — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Montserrat SIERRA COLOMINA, MD — CHU Toulouse
- Study coordinator: Caroline Peyrot, CRA
- Email: peyrot.c@chu-toulouse.fr
- Phone: 05 61 77 84 86
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.